熔点	-106 ºC***
沸点	188.5 ºC (764 Torr)**
闪点	71.1±6.5 ºC, 计算值*
密度	0.823 g/cm3 (25 ºC)**
折射率	1.4268 (589.3 nm 20 ºC)****

没有数据	没有数据

来源	SDS样本
没有数据	没有数据

产品合成路线

更多

名称	CAS号

更多

文章

同行评议文献

Metabolism of nilutamide in rat lung.Kjetil Ask et al.Biochemical pharmacology, 71(3), 377-385 (2005-11-30) Antiandrogenic activity of pyrethroid pesticides and their metabolite in reporter gene assay.Hong Sun et al.Chemosphere, 66(3), 474-479 (2006-07-22) Androgenic and antiandrogenic effects and expression of androgen receptor in mouse embryonic stem cells.Chih-Yang Chang et al.Fertility and sterility, 85 Suppl 1, 1195-1203 (2006-04-18) Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells.Hideki Koizumi et al.FEBS letters, 584(11), 2440-2444 (2010-04-27) Bioactivation and hepatotoxicity of nitroaromatic drugs.Urs A Boelsterli et al.Current drug metabolism, 7(7), 715-727 (2006-11-01) Nontranscriptional regulation of cardiac repolarization currents by testosterone.Chang-Xi Bai et al.Circulation, 112(12), 1701-1710 (2005-09-15) Nilutamide: an antiandrogen for the treatment of prostate cancer.E J Dole et al.The Annals of pharmacotherapy, 31(1), 65-75 (1997-01-01) Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).A Oliver Sartor et al.Cancer, 112(11), 2393-2400 (2008-04-03) Delayed dark adaptation caused by nilutamide.Patrick Chan et al.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 28(2), 158-159 (2008-06-20) Zinc mediates the action of androgen in acting as a downstream effector of luteinizing hormone on oocyte maturation in zebrafish†.Jianzhen Li et al.Biology of reproduction, 100(2), 468-478 (2018-11-13) Signaling pathway of nitric oxide production induced by ginsenoside Rb1 in human aortic endothelial cells: a possible involvement of androgen receptor.Jing Yu et al.Biochemical and biophysical research communications, 353(3), 764-769 (2007-01-02) Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.Richard Choo et al.International journal of radiation oncology, biology, physics, 75(2), 407-412 (2009-02-13) Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide.Olivier Payen et al.Journal of medicinal chemistry, 51(6), 1791-1799 (2008-02-29) Watchful waiting beats androgen deprivation therapy in early prostate cancer.Vicki Brower Journal of the National Cancer Institute, 100(21), 1494-1496 (2008-10-30) Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy.Johan F Langenhuijsen et al.Urologic oncology, 29(1), 52-57 (2009-06-16) A bifunctional colchicinoid that binds to the androgen receptor.Nima Sharifi et al.Molecular cancer therapeutics, 6(8), 2328-2336 (2007-08-19) Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3.Jun-ichi Asaka et al.Pharmaceutical research, 23(4), 697-704 (2006-03-22) A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.Nancy B Davis et al.BJU international, 96(6), 787-790 (2005-09-13) Anti-androgen effects of cypermethrin on the amino- and carboxyl-terminal interaction of the androgen receptor.Jin-Xia Hu et al.Toxicology, 292(2-3), 99-104 (2011-12-17) Phase I and phase II reductive metabolism simulation of nitro aromatic xenobiotics with electrochemistry coupled with high resolution mass spectrometry.Ugo Bussy et al.Analytical and bioanalytical chemistry, 406(28), 7253-7260 (2014-09-23) Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.D J Du Plessis Urology, 37(2 Suppl), 20-24 (1991-01-01) Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds.Niraj S Trasi et al.The journal of physical chemistry. B, 118(33), 9974-9982 (2014-07-31) A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.Shan Lu et al.Molecular cancer therapeutics, 6(7), 2057-2064 (2007-07-11) Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.M G Harris et al.Drugs & aging, 3(1), 9-25 (1993-01-01) Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice.Jennifer Keiser et al.The Journal of antimicrobial chemotherapy, 65(9), 1991-1995 (2010-06-26) Pharmacokinetics and metabolism of nilutamide.P J Creaven et al.Urology, 37(2 Suppl), 13-19 (1991-01-01) Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.Masayasu Urushibara et al.The Prostate, 67(8), 799-807 (2007-03-22) Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.Richard Choo et al.International journal of radiation oncology, biology, physics, 75(4), 983-989 (2009-05-05) Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.Ravi A Madan et al.Clinical cancer research : an official journal of the American Association for Cancer Research, 14(14), 4526-4531 (2008-07-17) High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.Yun Hua et al.Assay and drug development technologies, 12(7), 395-418 (2014-09-03) Fulminant hepatic failure due to nilutamide hepatotoxicity.Shehzad N Merwat et al.Digestive diseases and sciences, 54(4), 910-913 (2008-08-09) Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.Rupesh Raina et al.Asian journal of andrology, 9(2), 253-258 (2007-03-06) Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/akt pathway.Jing Yu et al.Endocrinology, 151(4), 1822-1828 (2010-03-03)

备注